The renewed and expanded agreements provide improved commercial conditions, including more competitive pricing, optimized contractual terms, and enhanced supply security. These improvements will ...
Strong Buy reiterated with a €8.37 target price following the 21 January 2026 Flash; last close on 22 January 2026: ...
The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for ENHERTU ® (trastuzumab deruxtecan) as a monotherapy for adult patients with HER2 ...
The multi‑year renewal strengthens ABL’s integrated platform, improving revenue visibility and supporting the Group’s ...
Breast exams, birth control and family planning are just some of the reasons not to skip your annual ob-gyn appointment.
"The key to her story is the power of proactive health management," Dr. Elias Obeid, a medical oncologist, told The Post.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results